|
US4722848A
(en)
|
1982-12-08 |
1988-02-02 |
Health Research, Incorporated |
Method for immunizing animals with synthetically modified vaccinia virus
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
US5391481A
(en)
|
1990-08-31 |
1995-02-21 |
The Trustees Of Columbia University |
Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
|
|
GB9022040D0
(en)
|
1990-10-10 |
1990-11-21 |
Biopharm Ltd |
Platelet adhesion inhibitor
|
|
US5851794A
(en)
|
1990-10-22 |
1998-12-22 |
Alfa Laval Ab |
Collagen binding protein as well as its preparation
|
|
US5173414A
(en)
|
1990-10-30 |
1992-12-22 |
Applied Immune Sciences, Inc. |
Production of recombinant adeno-associated virus vectors
|
|
JPH07505881A
(en)
|
1992-04-10 |
1995-06-29 |
ザ ジェネラル ホスピタル コーポレイション |
Cartilage matrix protein and its use
|
|
US5491130A
(en)
|
1992-11-10 |
1996-02-13 |
The United States Of America As Represented By The Department Of Health And Human Services |
Peptide inhibitors of fibronectin and related collagen-binding proteins
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5849589A
(en)
|
1996-03-11 |
1998-12-15 |
Duke University |
Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
|
|
EP0950068B1
(en)
|
1996-05-16 |
2005-11-09 |
THE TEXAS A&M UNIVERSITY SYSTEM |
Collagen binding protein compositions and methods of use
|
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
EP1037927B1
(en)
|
1997-12-08 |
2004-05-19 |
Lexigen Pharmaceuticals Corp. |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6387663B1
(en)
|
1998-07-31 |
2002-05-14 |
University Of Southern California |
Targeting pharmaceutical agents to injured tissues
|
|
WO2000021989A1
(en)
|
1998-10-09 |
2000-04-20 |
Medimmune, Inc. |
Decorin binding proteins dbp a and b and genes encoding them
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US6566489B1
(en)
|
1999-03-15 |
2003-05-20 |
The General Hospital Corporation |
Syndecan-4 binding protein (S4BP) and uses thereof
|
|
US6864235B1
(en)
|
1999-04-01 |
2005-03-08 |
Eva A. Turley |
Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
|
|
US6908994B1
(en)
|
1999-05-10 |
2005-06-21 |
The Texas A&M University System |
Collagen-binding proteins from enterococcal bacteria
|
|
AU5495500A
(en)
|
1999-06-16 |
2001-01-02 |
The Texas A & M University System |
Decorin binding protein essential peptides and methods of use
|
|
WO2000078800A2
(en)
|
1999-06-18 |
2000-12-28 |
Medimmune, Inc. |
Combined decorin binding protein and outer surface protein compositions and methods of use
|
|
CN1250288C
(en)
|
1999-12-15 |
2006-04-12 |
研究发展基金会 |
Beta glycan as an inhibin receptor and uses thereof
|
|
US6777547B1
(en)
|
2000-01-31 |
2004-08-17 |
Andreas Podbielski |
Collagen-binding proteins from streptococcus pyogenes
|
|
US6517838B1
(en)
|
2000-06-16 |
2003-02-11 |
The Texas A&M University System |
Decorin binding protein essential peptides and methods of use
|
|
AU2001292943A1
(en)
|
2000-09-21 |
2002-04-02 |
The Brigham And Women's Hospital, Inc. |
Prevention and treatment of streptococcal and staphylococcal infection
|
|
AU2002315857B2
(en)
|
2001-06-22 |
2007-07-26 |
Kaisha, Chugai Seiyaku Kabushiki |
Cell proliferation inhibitors containing anti-glypican 3 antibody
|
|
US8192744B2
(en)
|
2002-08-26 |
2012-06-05 |
Ibcc Holding As |
Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation
|
|
US7488792B2
(en)
|
2002-08-28 |
2009-02-10 |
Burnham Institute For Medical Research |
Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
|
|
GB0406415D0
(en)
|
2004-03-22 |
2004-04-21 |
Inst Of Cancer Res The |
Materials and methods for treatment of cancer
|
|
US20070259380A1
(en)
|
2004-05-20 |
2007-11-08 |
Kyoichi Sumida |
Method for Measuring Hyaluronic Acid Using Hyaluronic Acid Binding Protein
|
|
WO2005124356A2
(en)
|
2004-06-18 |
2005-12-29 |
Roche Diagnostics Gmbh |
Use of protein cbp2 as a marker for colorectal cancer
|
|
CN111925445A
(en)
|
2004-07-09 |
2020-11-13 |
中外制药株式会社 |
Anti-glypican 3 antibody
|
|
US7820401B2
(en)
|
2004-08-23 |
2010-10-26 |
Albert Einstein College Of Medicine Of Yeshiva University |
Collagen VI and cancer
|
|
US20090142345A1
(en)
|
2005-03-15 |
2009-06-04 |
Takeda Pharmaceutical Company Limited |
Prophylactic/therapeutic agent for cancer
|
|
CA2610791C
(en)
|
2005-06-08 |
2015-12-01 |
Cangene Corporation |
Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
|
|
CN105330741B
(en)
|
2005-07-01 |
2023-01-31 |
E.R.施贵宝&圣斯有限责任公司 |
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
|
|
EP1999154B1
(en)
|
2006-03-24 |
2012-10-24 |
Merck Patent GmbH |
Engineered heterodimeric protein domains
|
|
EP1864996A1
(en)
|
2006-06-06 |
2007-12-12 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Peptide associated with rheumatic fever (PARF) and its use as a diagnostic marker.
|
|
HU0600578D0
(en)
|
2006-07-13 |
2006-09-28 |
Szilak Labor Bioinformatikai E |
Nuclear protein transport
|
|
WO2008018519A1
(en)
|
2006-08-08 |
2008-02-14 |
Seikagaku Corporation |
Method for determination of molecular weight of hyaluronic acid
|
|
US8465732B2
(en)
|
2007-01-19 |
2013-06-18 |
Cornell Research Foundation, Inc. |
Endothelial cells expressing adenovirus E4ORF1 and methods of use thereof
|
|
RS54624B1
(en)
|
2007-07-17 |
2016-08-31 |
E. R. Squibb & Sons, L.L.C. |
Monoclonal antibodies against glypican-3
|
|
JP6157046B2
(en)
|
2008-01-07 |
2017-07-05 |
アムジェン インコーポレイテッド |
Method for generating antibody Fc heterodimer molecules using electrostatic steering effect
|
|
JP5619603B2
(en)
|
2008-03-17 |
2014-11-05 |
国立大学法人宮崎大学 |
Method for detecting hepatoma cells using anti-glypican 3 antibody
|
|
US20090297479A1
(en)
|
2008-03-28 |
2009-12-03 |
Kiyoshi Ariizumi |
Dc-hil conjugates for treatment of t-cell disorders
|
|
BRPI0906309A2
(en)
|
2008-04-02 |
2020-05-26 |
Macrogenics, Inc |
IMMUNOGLOBULIN, ANTIBODY, USE OF ANTIBODY AND PHARMACEUTICAL COMPOSITION
|
|
WO2009128448A1
(en)
|
2008-04-15 |
2009-10-22 |
和光純薬工業株式会社 |
Novel protein capable of binding to hyaluronic acid, and method for measurement of hyaluronic acid using the same
|
|
WO2010033866A2
(en)
|
2008-09-19 |
2010-03-25 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma
|
|
GB0818273D0
(en)
|
2008-10-06 |
2008-11-12 |
Cambridge Entpr Ltd |
Modulation of cellular activity and differentiation
|
|
KR101105428B1
(en)
|
2009-02-12 |
2012-01-17 |
경북대학교 산학협력단 |
A specific peptide targeting glypican-3
|
|
EP2417159A1
(en)
|
2009-04-07 |
2012-02-15 |
Roche Glycart AG |
Bispecific anti-erbb-3/anti-c-met antibodies
|
|
US20120100106A1
(en)
|
2009-05-04 |
2012-04-26 |
Purdue Research Foundation |
Collagen-binding synthetic peptidoglycans for wound healing
|
|
KR101588598B1
(en)
|
2009-08-17 |
2016-01-29 |
로슈 글리카트 아게 |
Targeted immunoconjugates
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
US9150663B2
(en)
|
2010-04-20 |
2015-10-06 |
Genmab A/S |
Heterodimeric antibody Fc-containing proteins and methods for production thereof
|
|
TWI586806B
(en)
|
2010-04-23 |
2017-06-11 |
建南德克公司 |
Production of heteromultimeric proteins
|
|
JP5758004B2
(en)
|
2010-08-24 |
2015-08-05 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Bispecific antibodies comprising Fv fragments stabilized by disulfides
|
|
WO2012032080A1
(en)
|
2010-09-07 |
2012-03-15 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H |
Stabilised human fc
|
|
US8906649B2
(en)
|
2010-09-27 |
2014-12-09 |
Janssen Biotech, Inc. |
Antibodies binding human collagen II
|
|
CA2815266C
(en)
|
2010-11-05 |
2023-09-05 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
|
CA2817779C
(en)
|
2010-11-15 |
2019-02-19 |
Pieris Ag |
Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
|
|
WO2012073985A1
(en)
*
|
2010-11-30 |
2012-06-07 |
中外製薬株式会社 |
Cytotoxicity-inducing therapeutic agent
|
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
EP3971206A1
(en)
*
|
2011-02-10 |
2022-03-23 |
Roche Glycart AG |
Mutant interleukin-2 polypeptides
|
|
CN103476795B
(en)
|
2011-03-29 |
2016-07-06 |
罗切格利卡特公司 |
Antibody Fc variant
|
|
EP3070104B1
(en)
|
2011-04-19 |
2017-12-27 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Human monoclonal antibodies specific for glypican-3 and use thereof
|
|
EA201892619A1
(en)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
|
|
HUE031596T2
(en)
|
2011-05-24 |
2017-07-28 |
Symic Ip Llc |
Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
|
|
WO2013012733A1
(en)
*
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
|
ES2671728T3
(en)
*
|
2011-10-11 |
2018-06-08 |
Universität Zürich Prorektorat Mnw |
Combination medicament comprising IL-12 and an agent for blocking T-lymphocyte inhibitor molecules for tumor therapy
|
|
WO2013070468A1
(en)
|
2011-11-08 |
2013-05-16 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
|
EP2804586A4
(en)
|
2012-01-19 |
2016-03-16 |
Univ Johns Hopkins |
Biomaterials comprising hyaluronic acid binding peptides and bifunctional biopolymer molecules for hyaluronic acid retention and tissue engineering applications
|
|
MX360110B
(en)
|
2012-04-20 |
2018-10-23 |
Merus Nv |
Methods and means for the production of ig-like molecules.
|
|
US9751919B2
(en)
|
2012-05-04 |
2017-09-05 |
Emergent Biosolutions Canada Inc. |
Antimicrobial compositions comprising a hyaluronic acid binding peptide and a β-lactam antibiotic
|
|
US9522940B2
(en)
|
2012-05-23 |
2016-12-20 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
|
|
CN104520331B
(en)
|
2012-06-01 |
2018-09-07 |
美国政府(由卫生和人类服务部的部长所代表) |
High-affinity monoclonal antibody of glypican-3 and application thereof
|
|
BR112015002263A2
(en)
|
2012-08-02 |
2017-12-12 |
Hoffmann La Roche |
fusion polypeptide, dimeric fusion polypeptide, method for producing a soluble fc receptor, use of an immobilized fusion polypeptide and pharmaceutical composition
|
|
CN104508133B
(en)
|
2012-08-02 |
2018-04-20 |
弗·哈夫曼-拉罗切有限公司 |
Method for producing monomer and multimeric molecule and application thereof
|
|
NZ702241A
(en)
|
2012-08-07 |
2018-04-27 |
Roche Glycart Ag |
Composition comprising two antibodies engineered to have reduced and increased effector function
|
|
US9714291B2
(en)
*
|
2012-10-05 |
2017-07-25 |
Kyowa Hakko Kirin Co., Ltd |
Heterodimer protein composition
|
|
WO2014084607A1
(en)
|
2012-11-27 |
2014-06-05 |
아주대학교산학협력단 |
Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
|
|
TR201809571T4
(en)
*
|
2013-03-15 |
2018-07-23 |
Hoffmann La Roche |
IL-22 polypeptides and IL-22 fc fusion proteins and methods of use.
|
|
US20140302037A1
(en)
*
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
|
ES2821753T3
(en)
|
2013-03-15 |
2021-04-27 |
Lilly Co Eli |
Fab and bispecific antibody production procedures
|
|
AU2014232416B2
(en)
|
2013-03-15 |
2017-09-28 |
Xencor, Inc. |
Modulation of T Cells with Bispecific Antibodies and FC Fusions
|
|
MX2015015060A
(en)
|
2013-04-29 |
2016-02-25 |
Hoffmann La Roche |
Fc-receptor binding modified asymmetric antibodies and methods of use.
|
|
WO2014194100A1
(en)
|
2013-05-29 |
2014-12-04 |
The Regents Of The University Of California |
Anti-cspg4 fusions with interferon for the treatment of malignancy
|
|
AR096891A1
(en)
|
2013-07-12 |
2016-02-03 |
Hanmi Pharm Ind Co Ltd |
CONJUGATE OF BIOMOLOGICALLY ACTIVE POLYPEPTIDE MONOMER AND CONJUGATE OF FRAGMENTO FC OF IMMUNOGLOBULINA, THAT SHOWS CLEARING THROUGH REDUCED RECEPTOR, AND THE METHOD FOR PREPARING THE SAME
|
|
UA117289C2
(en)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Multispecific antibodies
|
|
US20160032007A1
(en)
|
2014-04-28 |
2016-02-04 |
Duke University |
Human Antibody Fragments Against Chondroitin Sulfate Proteoglycan 4 (CSPG4)
|
|
HRP20231139T1
(en)
|
2014-05-06 |
2024-01-05 |
F. Hoffmann - La Roche Ag |
Production of heteromultimeric proteins using mammalian cells
|
|
JP6822849B2
(en)
|
2014-06-27 |
2021-01-27 |
イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． |
Multispecific NKp46 binding protein
|
|
WO2016007919A2
(en)
|
2014-07-11 |
2016-01-14 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
|
MA40764A
(en)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
THERAPEUTIC AGENT INDUCING CYTOTOXICITY
|
|
MX2017005148A
(en)
|
2014-11-06 |
2017-08-08 |
Hoffmann La Roche |
Fc-region variants with modified fcrn-binding and methods of use.
|
|
AR102522A1
(en)
|
2014-11-06 |
2017-03-08 |
Hoffmann La Roche |
FC REGION VARIATIONS WITH MODIFIED PROPERTIES OF UNION TO FCRN AND PROTEIN A
|
|
EP3218413A4
(en)
|
2014-11-12 |
2018-03-28 |
Memorial Sloan-Kettering Cancer Center |
Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof
|
|
EP3271396B1
(en)
|
2015-03-20 |
2022-03-16 |
Orbsen Therapeutics Limited |
Modulators of syndecan-2 and uses thereof
|
|
US10881711B2
(en)
|
2015-04-06 |
2021-01-05 |
The General Hospital Corporation |
Anti-CSPG4 reagents and methods of treating cancer
|
|
US11370845B2
(en)
|
2015-06-24 |
2022-06-28 |
Keio University |
Anti-glypican-1-immunizing antigen receptor
|
|
LT3331902T
(en)
*
|
2015-08-07 |
2021-08-10 |
ALX Oncology Inc. |
Constructs having a sirp-alpha domain or variant thereof
|
|
AU2016322919B2
(en)
|
2015-09-14 |
2022-12-22 |
Regents Of The University Of Minnesota |
NK cells exhibiting an adaptive phenotype and methods for preparing and for using
|
|
CN108884147B
(en)
|
2015-09-23 |
2024-02-27 |
百时美施贵宝公司 |
Fibronectin-based scaffold molecules that bind glypican 3
|
|
US11098100B2
(en)
|
2015-10-06 |
2021-08-24 |
Regents Of The University Of Minnesota |
Therapeutic compounds and methods
|
|
KR101851380B1
(en)
|
2015-10-12 |
2018-04-23 |
아주대학교산학협력단 |
Method to generate CH3 domain mutant pairs of heterodimeric Fc using yeast mating and CH3 domain mutant pairs thereby
|
|
KR101796688B1
(en)
|
2015-10-29 |
2017-12-01 |
재단법인 목암생명과학연구소 |
Novel Antibody Against Glypican 3, and Pharmaceuitical Composition Comprising the Same
|
|
CN109415435B
(en)
|
2016-07-04 |
2024-01-16 |
豪夫迈·罗氏有限公司 |
Novel antibody forms
|
|
EP3494135A1
(en)
|
2016-08-02 |
2019-06-12 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
|
|
WO2018030806A1
(en)
*
|
2016-08-10 |
2018-02-15 |
아주대학교산학협력단 |
Cytokine fused to immunoglobulin fc heterodimer and pharmaceutical composition comprising same
|
|
KR102050463B1
(en)
|
2016-08-10 |
2019-11-29 |
아주대학교산학협력단 |
Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
|
|
KR101928981B1
(en)
*
|
2016-09-02 |
2018-12-13 |
고려대학교 산학협력단 |
Heterodimeric Fc-fused IL-21 and Pharmaceutical Composition Comprising the Same
|
|
KR102649972B1
(en)
*
|
2016-10-14 |
2024-03-22 |
젠코어 인코포레이티드 |
IL15/IL15Rα heterodimeric Fc-fusion protein
|
|
JP2020508997A
(en)
|
2017-02-20 |
2020-03-26 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Proteins that bind to Her2, NKG2D and CD16
|
|
US11248022B2
(en)
|
2017-03-08 |
2022-02-15 |
The Regents Of The University Of Michigan |
Glypican-3 peptide reagents and methods
|
|
CN110662560B
(en)
|
2017-03-27 |
2024-06-28 |
豪夫迈·罗氏有限公司 |
Improved antigen binding receptors
|
|
JP7254029B2
(en)
|
2017-04-26 |
2023-04-07 |
田辺三菱製薬株式会社 |
SYNDECAN-1 (CD138) binding agents and uses thereof
|
|
EP3617231A4
(en)
|
2017-04-28 |
2021-04-07 |
National University Corporation Kochi University |
Anti-gpc-1 antibody
|
|
WO2018217989A1
(en)
*
|
2017-05-24 |
2018-11-29 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
JP2019014449A
(en)
|
2017-07-10 |
2019-01-31 |
トヨタ自動車株式会社 |
Vehicular power transmission device
|
|
BR112020004489A2
(en)
|
2017-09-07 |
2020-09-08 |
Dragonfly Therapeutics, Inc. |
nkg2d-binding proteins, cd16 and a tumor-associated antigen
|
|
CA3074483A1
(en)
*
|
2017-09-21 |
2019-03-28 |
Merck Patent Gmbh |
Fusion protein comprising an fgf-18 moiety
|
|
AU2018334886A1
(en)
*
|
2017-09-22 |
2020-04-09 |
WuXi Biologics Ireland Limited |
Novel bispecific polypeptide complexes
|
|
BR112020007154A2
(en)
|
2017-10-20 |
2020-09-29 |
F. Hoffmann-La Roche Ag |
method for producing a heterodimeric polypeptide and polypeptides
|
|
BR112020015994A2
(en)
|
2018-02-08 |
2020-12-15 |
Dragonfly Therapeutics, Inc. |
CANCER COMBINATION THERAPY INVOLVING MULTI-SPECIFIC BINDING PROTEINS THAT ACTIVATE NATURAL KILLER CELLS
|
|
DE102018208278A1
(en)
|
2018-05-25 |
2019-11-28 |
Robert Bosch Gmbh |
Operational assistance procedure, control unit, operational assistance system and working device
|
|
JP2021531268A
(en)
*
|
2018-07-11 |
2021-11-18 |
モメンタ ファーマシューティカルズ インコーポレイテッド |
Compositions and Methods for Modified Fc Antigen Binding Domain Constructs
|
|
SG11202103192RA
(en)
*
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
|
WO2020086758A1
(en)
*
|
2018-10-23 |
2020-04-30 |
Dragonfly Therapeutics, Inc. |
Heterodimeric fc-fused proteins
|